1,4-Ditert-butyl-2,3,6,7-tetrahydroazepine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 英文名称: 1,4-Ditert-butyl-2,3,6,7-tetrahydroazepine
• 英文别名: 1,4-ditert-butyl-2,3,6,7-tetrahydroazepine
• 化学式: C₁₄H₂₇N
• 分子量: 209.37
• InChiKey: WZVPHYUTKQSQFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Substituted Pyrazole Derivatives As Selective CDK12/13 Inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US20190308951A1

  公开（公告）日：2019-10-10

  The present invention provides substituted pyrazole derivatives of formula (I) which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions with at least one of the substituted pyrazole derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.

  本发明提供了公式（I）的取代吡唑衍生物，其在治疗上具有选择性CDK12/13抑制剂的治疗作用。这些化合物在哺乳动物中用于治疗和/或预防与CDK12/13相关的疾病和/或疾病。本发明还提供了这些化合物的制备以及含有公式（I）的至少一种取代吡唑衍生物或其药学上可接受的盐、N-氧化物或立体异构体的药物组合物。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：PLEXXIKON INC.

  公开号：US20140128390A1

  公开（公告）日：2014-05-08

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

  本文描述了对c-kit蛋白激酶或携带任何突变的突变c-kit蛋白激酶起作用的化合物，以及制备和使用这种化合物治疗与c-kit蛋白激酶和突变c-kit蛋白激酶的异常活性相关的疾病和病状的方法。
• Compounds and methods for kinase modulation, and indications therefor
  申请人：Plexxikon Inc.

  公开号：US10227357B2

  公开（公告）日：2019-03-12

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

  本文描述了对具有任何突变的 c-kit 蛋白激酶或突变 c-kit 蛋白激酶具有活性的化合物，以及制造和使用此类化合物治疗与 c-kit 蛋白激酶和突变 c-kit 蛋白激酶异常活性相关的疾病和病症的方法。
• Substituted pyrazole derivatives as selective CDK12/13 inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US10894786B2

  公开（公告）日：2021-01-19

  The present invention provides substituted pyrazole derivatives of formula (I) which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions with at least one of the substituted pyrazole derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.

  本发明提供了式 (I) 的取代吡唑衍生物 作为选择性 CDK12/13 抑制剂具有治疗作用。这些化合物可用于治疗和/或预防哺乳动物体内与 CDK12/13 相关的疾病和/或失调。本发明还提供了至少一种式（I）的取代吡唑衍生物或其药学上可接受的盐、N-氧化物或立体异构体的化合物和药物组合物的制备方法。